Canandaigua National Bank & Trust Co. cut its position in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 2.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,253 shares of the company’s stock after selling 100 shares during the period. Canandaigua National Bank & Trust Co.’s holdings in Zimmer Biomet Holdings were worth $512,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the stock. BlackRock Institutional Trust Company N.A. raised its position in shares of Zimmer Biomet Holdings by 5.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 4,644,015 shares of the company’s stock worth $495,191,000 after buying an additional 221,345 shares during the period. Nordea Investment Management AB raised its position in shares of Zimmer Biomet Holdings by 5.9% in the second quarter. Nordea Investment Management AB now owns 4,087,633 shares of the company’s stock worth $492,069,000 after buying an additional 226,480 shares during the period. BlackRock Fund Advisors raised its position in shares of Zimmer Biomet Holdings by 3.6% in the first quarter. BlackRock Fund Advisors now owns 3,166,705 shares of the company’s stock worth $337,666,000 after buying an additional 109,646 shares during the period. First Manhattan Co. raised its position in shares of Zimmer Biomet Holdings by 4.6% in the first quarter. First Manhattan Co. now owns 2,578,758 shares of the company’s stock worth $274,972,000 after buying an additional 112,931 shares during the period. Finally, Norges Bank bought a new position in shares of Zimmer Biomet Holdings during the fourth quarter worth $167,151,000. Institutional investors own 88.30% of the company’s stock.

Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 2.12% on Wednesday, reaching $127.19. 896,658 shares of the company’s stock were exchanged. The firm has a 50-day moving average of $128.38 and a 200-day moving average of $119.25. The firm has a market capitalization of $25.44 billion, a price-to-earnings ratio of 116.16 and a beta of 0.95. Zimmer Biomet Holdings Inc. has a 12 month low of $88.27 and a 12 month high of $133.19.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Thursday, July 28th. The company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.97 by $0.05. Zimmer Biomet Holdings had a net margin of 1.68% and a return on equity of 16.12%. The firm earned $1.93 billion during the quarter, compared to the consensus estimate of $1.90 billion. During the same period in the prior year, the firm earned $1.58 EPS. The business’s revenue was up 65.6% on a year-over-year basis. On average, equities analysts expect that Zimmer Biomet Holdings Inc. will post $7.97 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 28th. Stockholders of record on Friday, September 23rd will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date of this dividend is Wednesday, September 21st. Zimmer Biomet Holdings’s dividend payout ratio is 157.38%.

Several equities analysts recently weighed in on the stock. JMP Securities lifted their target price on shares of Zimmer Biomet Holdings from $131.00 to $145.00 and gave the company a “market outperform” rating in a report on Friday, July 29th. Jefferies Group restated a “buy” rating and set a $135.00 target price on shares of Zimmer Biomet Holdings in a report on Wednesday, June 8th. Barclays PLC lifted their target price on shares of Zimmer Biomet Holdings from $140.00 to $145.00 and gave the company an “overweight” rating in a report on Tuesday, August 23rd. RBC Capital Markets set a $143.00 target price on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a report on Wednesday, September 14th. Finally, Royal Bank Of Canada restated a “buy” rating and set a $132.00 target price on shares of Zimmer Biomet Holdings in a report on Wednesday, June 8th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty-two have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $132.36.

In other news, VP Tony W. Collins sold 1,287 shares of the stock in a transaction on Friday, August 12th. The shares were sold at an average price of $129.16, for a total value of $166,228.92. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Daniel P. Florin sold 15,000 shares of the stock in a transaction on Monday, July 11th. The shares were sold at an average price of $124.98, for a total transaction of $1,874,700.00. Following the completion of the transaction, the chief financial officer now owns 16,983 shares of the company’s stock, valued at approximately $2,122,535.34. The disclosure for this sale can be found here. 1.22% of the stock is currently owned by insiders.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc. (NYSE:ZBH).

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.